WebMD Health News
Louise Chang, MD
Feb. 9, 2010 -- Non-hospitalized patients with a flare-up of inflammatory bowel disease are 16 times more likely to develop potentially life-threatening blood clots as people without the bowel disorder, new research reveals.
While the risk is still quite small for individuals with Crohn's disease and ulcerative colitis, which are forms of inflammatory bowel disease (IBD), the findings suggest that active IBD is a bigger risk factor for blood clots than has been previously recognized.
Blood clots, known medically as venous thromboembolisms, can become deadly when they break away from the large veins in the legs or groin and move to the lungs. The Surgeon General estimates that between 300,000 and 1.2 million Americans experience such clots each year, and more than 100,000 die from them.
In earlier studies, researchers reported that most IBD patients who develop blood clots do so when their disease is symptomatic, rather than when it is in remission. For this reason, many hospitalized IBD patients receive anticlotting drugs like heparin to reduce their blood clot risk. But the risk to non-hospitalized IBD patients in the active, or flare-up, phase of the disease has not been well understood.
In an effort to assess this risk, researchers analyzed a database in the U.K. that included information on patients with and without IBD.
The analysis included 13,756 patients treated for IBD between November 1987 and July 2001 and 71,672 people without the disease who served as a comparison group.
Among the results:
While the overall risk for developing a blood clot was greatest among patients hospitalized with IBD, the relative risk was greatest for symptomatic IBD patients who were not hospitalized.
Compared to non-hospitalized people without IBD, these patients were 16 times more likely to develop a potentially life-threatening blood clot.
The study appears online Feb. 9 in The Lancet.
Study researcher Matthew J. Grainge, MD, of the University of Nottingham, and colleagues conclude that patients with symptomatic IBD who are not hospitalized may benefit from short-term treatment with intravenous heparin or other anticlotting drugs.
But in an editorial published with the study, University of Toronto inflammatory bowel disease specialist Geoffrey C. Nguyen, MD, PhD, writes that this may be premature.
He notes that treating non-hospitalized patients with daily injections of heparin has no proven effectiveness and would add to the disease burden.
Johns Hopkins University School of Medicine IBD specialist Mark Lazarev, MD, tells WebMD that a study comparing treatment vs. non-treatment for reducing blood clot risk would be expensive and difficult to do.
"You would need a large number of patients because the individual risk is very low," he says.
Stephan R. Targan, MD, who directs the IBD Center at Cedars-Sinai Medical Center in Los Angeles, agrees it is too soon to talk about treating all patients with symptomatic IBD to reduce their blood clot risk.
"It doesn't really make sense to talk about treating the entire population with active IBD," he tells WebMD. "Maybe if we knew more about what predisposes people with these conditions to develop blood clots we could target such treatments. But right now we can't do that."
SOURCES: Grainge, M.J. The Lancet, Feb. 9, 2010; online edition.News release, The Lancet.Mark Lazarev, MD, assistant professor of medicine, Johns Hopkins University
School of Medicine, Baltimore.Stephen R. Targan, MD, director, Inflammatory Bowel Disease Center and
division of gastroenterology, Cedars-Sinai Medical Center; professor of
medicine, David Geffen School of Medicine, University of California, Los
Angeles.Circulation, 2009; vol 119: pp e480-482.
Here are the most recent story comments.View All
© 2015 Ramar Communications |
Site Map |
Privacy Statement |
Copyright & Trademark Notice |
EEO Report |
FCC Public Files |
Closed Captioning |